A surrogate marker to monitor angiogenesis at last
- 31 January 2005
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 7 (1) , 3-4
- https://doi.org/10.1016/j.ccr.2004.12.014
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug DevelopmentClinical Cancer Research, 2004
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerNature Medicine, 2004
- Imaging of angiogenesis: from microscope to clinicNature Medicine, 2003
- Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular RiskNew England Journal of Medicine, 2003
- Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?Nature Reviews Cancer, 2002
- Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapyNature Medicine, 2001
- Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditionsNature Medicine, 2001
- Isolation of Putative Progenitor Endothelial Cells for AngiogenesisScience, 1997